Universal Epidemiology of Insidious Meningococcal Syndrome

Gjovalin Valsa
Pediatrics department, Rreshen Hospital, Albania

Enkelejda Shkurti
University of Medicine, Tirana, Albania

Abstract

Neisseria meningitidis is one of the principal sources of bacterial meningitis worldwide and can as well cause sepsis, pneumonia, and further expressions. In states with elevated widespread rates, the illness load puts a huge tension on the public health structure. The universal epidemiology of persistent meningococcal disease (IMD) diverges distinctly by area and in due course. This appraisal summarizes the burden of IMD in diverse states and recognizes the highest-incidence countries where habitual preventive programs aligned with Neisseria meningitidis would be essentially profitable in offering security. Accessible epidemiological figures from the past 20 years in World Health Organization and European Centre for Disease Prevention and Control assortments and available articles are comprised in this review, in addition to straight statements with important specialists in the area. The nations were clustered into high-, moderate-, and low-incidence states. The mainstream of countries in the elevated-incidence set are located in the African meningitis belt; several reasonable-incidence states are located in the European and African areas, and Australia, whereas low-incidence countries comprise numerous from Europe and the Americas. Precedence nations for vaccine involvement are high- and restrained-incidence nations where vaccine-avoidable serogroups prevail. Epidemiological records on burden of IMD are required in nations where this is not distinguished, predominantly in South-East Asia and Eastern Mediterranean areas, so evidence-based assessments concerning the application of meningococcal vaccines can be created.

Keywords: meningococcus, neisseria meningitidis, insidious meningococcal illness, meningitis, epidemiology, meningitis belt

Introduction

Neisseria meningitidis is one of the principal basis of bacterial meningitis worldwide and can furthermore cause sepsis, pneumonia, and further restricted diseases. There are 12 serogroups, but the mainstream of insidious meningococcal diseases are caused by individuals from the A, B, C, X, Y, or W-135 serogroups. The yearly quantity of insidious syndrome cases globally is approximated to be as a minimum 1.2 million, with 135,000 deaths linked to insidious meningococcal illness (IMD) [1,2]. In countries with elevated endemicity, the infection load puts an enormous harm on the public health scheme. The hazard of lasting hindering sequelae, comprising cognitive insufficiency, bilateral earshot loss, speed deficit, convulsions, image injury, hydrocephalus, and failure of limbs because of tissue necrosis, are uppermost in low profits countries, where the load of bacterial meningitis is supreme [3].

To fight IMD, many developed countries have comprised dissimilar formulations of meningococcal vaccine in their habit immunization agendas. A vaccine next to serogroup A has lately been established in the African meningitis belt, a region expanding from Senegal in the west to Ethiopia in the east [4,5]. Conversely, meningococcal vaccines remain underutilized internationally, mainly in source-restricted countries outside the African meningitis belt. To afford cost efficient proposals about the application of meningococcal vaccines, the country-detailed load of IMD must be recognized [6]. A broad review of IMD occurrence, counting all countries with no less than an essential observation infrastructure exposing IMD cases, was accomplished. The appraisal offers the most lately in print assault rates, predominant sero groups, and at-risk clusters from over 80 countries and arranges the facts consistent with precedence groups for vaccine intrusion.

Methods
Exploration approach and assortment criteria

Our basis for the epidemiological statistics comprised the National Library of Medicine (PubMed), the World Health Organization (WHO) website of the Weekly Epidemiological evidence, and the European Centre for Disease Prevention and Control. We investigated PubMed with the subsequent key phrases: “Neisseria meningitidis” or “meningococcus”.

The investigation was bounded to surveys of individuals, studies distributed in English, and dates of publication from 1995, to December 31, 2013. The primary investigation deferred 5320 outcomes from which surveys were rejected based on segregation criteria below. The data were acquired and comprised from WHO publications in the Weekly Epidemiological Record (WER) for the latest outlines from 10 African meningitis belt states. The European Union Insidious Bacterial Diseases Surveillance System (EU-IBIS), which is preserved by the European Centre for Disease Prevention and Control, was admitted for reorganized numbers for European countries and these facts were also comprised. We explored indication catalogs in all recognized articles for supplementary articles, and appraised abstracts and designates and chose surveys if it appeared they comprised features of meningococcal epidemiology. From the exceeding literature exploration we prohibited general global approximation (excluding the identification of unique data suggestions), or surveys that were bounded to immunology, medicine resistance, or further non-epidemiological features.

Organization of data

The WHO description of a meningococcal illness outbreak (>100 cases/100,000 inhabitants/year) relates exclusively to the meningitis belt. Supplementary countries infrequently skill epidemics with these elevated assault rates. We categorized countries regarding the level of endemic meningococcal illness as “elevated,” “restrained,” and “low” extension (Figure 1). This taxonomy is founded on state-detailed epidemiological facts with pre-identified cut offs of high, moderate, and low widespread groups.

Results

Epidemiology of meningococcal syndrome at national stage

Records on occurrence of meningococcal disease are presented underneath in Tables 1, 2 and 3. Countries are clustered into precedence areas regarding the descriptions beyond, by means of general and available statistics from the previous 20 years. States not registered in the table have inadequate accessible IMD epidemiological figures to access correct taxonomy. Considerable gaps in data limit explanation of IMD epidemiology in some elements of the globe. In many nations with IMD inspection, widespread marked vaccine expansion and rising exposure has diminished the burden of syndrome. In some endemic countries without immunization, high IMD assault rates maintain. The precise district epidemiology is recapitulated in Figure 2 and illustrated in terms of WHO areas below.

African region

The African Meningitis Belt, formerly distinguished by Lapeysonnie in 1963 [5] and adjusted in 1987, has the highest yearly occurrence of meningococcal illness in the world with cover up recurrent epidemics that comprise a chief public health load. Epidemics in the sub-Saharan area overlap with the dry period, which has led to a supposition for the probable task of low dampness and seasonal dust-wind carrying from the Sahara (the Harmattan) in harming the mucosa and producing painful coughing that helps diffusion [34,43].

Twenty-five states in the African area with an enormously high prevalence of meningococcal infection comprise the meningitis belt. To quickly notice the recurrent epidemics, a tough surveillance coordination subsists that observes the amount of cases on an constant basis for quick reaction. This area has lately gained from a main coalition of global health bodies that have expanded and are organizing an reasonable and effective vaccine beside serogroup A meningococcus, which causes the mainstream of illness in this region, at population level [44].
Figure 1. A categorization of countries according to IMD attack rates

Table 1. Countries with high endemic rates (>10 cases/100,000 population) and/or > =1 epidemic over the last 20 years

<table>
<thead>
<tr>
<th>Country</th>
<th>Year Incidence/100,000</th>
<th>Predominant Serogroup</th>
<th>Source</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>African Region</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Benin</td>
<td>1980–1999 6–57</td>
<td>[9,10]</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Burundi</td>
<td>1980–1999158</td>
<td>[9]</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cameroon</td>
<td>1–224</td>
<td>[13]</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chad</td>
<td>9.6–15.9</td>
<td>[12]</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cote de Ivoire</td>
<td>1980–1999 0–6</td>
<td>[14]</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Despite its relatively low attack rate, Cote de Ivoire is included in this table due to its location in the meningitis belt.

<table>
<thead>
<tr>
<th>Country</th>
<th>Year Incidence/100,000</th>
<th>Predominant Serogroup</th>
<th>Source</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ethiopia</td>
<td>0–104</td>
<td>A</td>
<td>[9,10]</td>
<td></td>
</tr>
<tr>
<td>Gambia</td>
<td>4–165</td>
<td>[9,15]</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ghana</td>
<td>0–108</td>
<td>[9,15]</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Guinea</td>
<td>0–17</td>
<td>[12]</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Guinea Bissau</td>
<td>0–133</td>
<td>[9]</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kenya</td>
<td>1990 267</td>
<td>[16]</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Mali  2004–2009  2.6–12.9  [12]
Mauritania  1980–1999  0–14  [9]
Namibia  1980–1999  0–165  [9]
Niger  2004–2009  7.8–90.7  [17]
Nigeria  0.7–52.6  [12]
RD Congo  7.3–23.7  [12]
Senegal  1980–1999  0–53 Incidence >50 in
Tanzania  1980–1999  0–19
Uganda  1980–1999  0–18  [14]

Eastern Mediterranean Region
Sudan 2008 * A  [12]
Despite lack of data Sudan is included in this table due to its location in the meningitis belt
Arabia mostly includes cases from the Hajj season.

European Region
No country in this region is in the high rate category

Region of the Americas
Uruguay  2001  30 (pre-vaccine) B  [19]. Vaccine comprising serogroup C, capsular polysaccharide and the outer
membrane vesicles of serogroup B meningococcus.

South-East Asia Region
No country in this region is in the high rate category

Western Pacific Region
New Zealand  1991–2000  17.4 (pre-vaccine) B  [20] An OMV vaccine for Serogroup,  2.6 (post-vaccine) B was introduced
in 2004.
Serogroup X, formerly an unusual reason of sporadic meningitis, has been accountable for eruptions among 2006 and
2010 in Kenya, Niger, Togo, Uganda, and Burkina Faso, the final with as a minimum of 1,300 cases of serogroup X
meningitis between the 6,732 accounted annual cases [45].
South Africa is comprised in the moderate-endemicity cluster, whereas other states in this area do not have sufficient data to allow the beginning of a population-based approximation of their proper prevalence rates.

**European region**

With the exclusion of a few states in the eastern fraction of the European Region, excellent surveillance records are accessible from main European nations. Serogroup B and C are accountable for the conventional of sickness, and achievement of a meningococcal immunization route with adequate vaccine revelation has contributed to declining extensive rates so that no state now decreases in the elevated-endemicity cluster. Fifteen countries from this area are classified as restrained endemicity and 18 as low. Current epidemiological supervision points out an boost of serogroup Y IMD in some divisions of Europe, which is currently the third most ordinary serogroup after B and C [23].

**Region of the Americas**

Uruguay stays the only nation from this area to have practiced high rates of IMD in the past 20 years. In 2001, it experienced a peak occurrence rate of meningococcal illness because of serogroup B and this prompted the foreword of the Cuban external membrane vesicle (OMV) B vaccine with superior exposure and a quick rejection in occurrence in following years. Brazil and Cuba have practiced restrained occurrence rates, but have furthermore seen important advantage from the preface of meningococcal vaccines in their residents [29]. Argentina, Canada, Chile, Columbia, Mexico, the United States have performed low periods of IMD in the timeframe explained by this assessment. Serogroup Y appeared in Colombia and Venezuela, where it became the common disease-causing serogroup in 2006 [19]. The US has a general meningococcal vaccine and Canada also suggests a vaccination dosage in this age cluster continuing primary immunization at 12 months of age. Other states in this area do not have sufficient data to permit population-based estimates of their factual incidence. South-East Asia Region Korea and Thailand are the only nations from these areas with available population-based approximations, which reveal low common rates. India has practiced recurring serogroup A outbreaks, the most current in 2005, but facts are frequently accessible only from great city centers [46]. Periodic and partial statistics from India, Bangladesh, Indonesia, Nepal, and Pakistan exclude their taxonomy, and no information is obtainable from Sri Lanka [36].

**Western Pacific**

New Zealand and Mongolia have confirmed high IMD prevalence. New Zealand practiced an outburst of serogroup B illness until a violent movement with the OMV vaccine was started in 2004 that has supplied partly to lowering the occurrence. Mongolia practiced serogroup A epidemics in the near the beginning 1990s. Australia at present presents mainly serogroup B illness with moderate assault rates following the foreword of a serogroup C vaccine saw a noticeable rejection in rates of illness caused by the C serogroup. China, Japan, Korea, Philippines, Singapore, Taiwan, and Thailand all present low stages of IMD. Other nations in this area do not have sufficient population-based information to permit assessment of their accurate incidence rates. In a lot of states with epidemiological figures, mainly in Europe and North America, the age allocation of meningococcal illness shows two peaks [6,47-49].

**Table 2. Countries with moderate endemic rates (2–10 cases/100,000 population per year)**

<table>
<thead>
<tr>
<th>Country</th>
<th>Year</th>
<th>Incidence/100,000 population</th>
<th>Predominant serogroup</th>
<th>Source</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>African Region</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>South Africa</td>
<td>2000–2005</td>
<td>0.8–4</td>
<td>B in Western Cape[22]</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Eastern Mediterranean Region</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>No country in this region is in the moderate rate category</td>
</tr>
</tbody>
</table>
European Region

Belgium 1999–2010 2.9 (pre-vaccine) B, C [23,24], A conjugate vaccine for group; 0.89 (post-vaccine) C was introduced in 2002

Denmark 1999–2010 1.19–3.5 B [23,24]

Greece 0.49–2.0 C [23,24]


A conjugate vaccine for group C was 2.19 (post-vaccine) introduced in 2001. Iceland 7.6 (pre-vaccine) B, C [23,24]

A conjugate vaccine for group C was 0.6 (post-vaccine) introduced in 2002

Lithuania 2004–2010 1.4–2.6* [23,24]

Luxemburg 1999–2010 0.2–5.68 * [23,24]

Malta 1994–2007 0.8–8.9 B, C [26]

Netherland 1999–2010 3.6 (pre-vaccine) B, C [23,24]

A conjugate vaccine for group C introduced in 2002

Norway 1992–2010 0.8–4.6B [23,27]

Portugal 2000–2010 0.74–3.0 B, C [23,28]

Spain 1999–2010 3.52 (pre-vaccine) B, C [23,24]

A conjugate vaccine for group C was 0.88 (post vaccine) C introduced in 2001

Switzerland 1999–2004 1.16–2.36 C [24]

A conjugate vaccine for group C introduced in 2005

Turkey 1997–2005 0.3–2.2 *[28]

United Kingdom 1999–2010 5.4 (pre-vaccine) B, C [23,24]

A conjugate vaccine for group C was 1.63 (post vaccine) C introduced in 1999

Region of the Americas

Brazil 1998–2006 1–4.5 B, now C[19]

A combined vaccine against serogroup B (OMV) and C (polysaccharide) was introduced in 1990

Cuba 1998–2003 3.4–8.5 (pre-vaccine) B [29]

South-East Asia Region

No country in this region is in the moderate rate category

Western Pacific Region


A conjugate vaccine for Serogroup
1.4 (post-vaccine) C was introduced in 2003
* Data not available.

Table 3. Countries with low endemic rates (<2 case/100,000 population per year)

<table>
<thead>
<tr>
<th>Country</th>
<th>Year</th>
<th>Incidence/100,000 population</th>
<th>Predominant serogroup</th>
<th>Source Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>African Region</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No country in this region is in the low rate category</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>European Region</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Austria</td>
<td>1999–2010</td>
<td>1.02–1.2 B, C</td>
<td>[23,24]</td>
<td></td>
</tr>
<tr>
<td>Bulgaria</td>
<td>2000–2010</td>
<td>0.11–1.1 *</td>
<td>[23,28]</td>
<td></td>
</tr>
<tr>
<td>Croatia</td>
<td>1997–2005</td>
<td>0.7–1.3 *</td>
<td>[28]</td>
<td></td>
</tr>
<tr>
<td>Cyprus</td>
<td>1997–2010</td>
<td>0.13–1.7 *</td>
<td>[23,28]</td>
<td></td>
</tr>
<tr>
<td>Czech Republic</td>
<td>1999–2010</td>
<td>0.57–1.0 B, C</td>
<td>[23,24]</td>
<td></td>
</tr>
<tr>
<td>Estonia</td>
<td>2001–2010</td>
<td>0.15–1.6 *</td>
<td>[23,28]</td>
<td></td>
</tr>
<tr>
<td>Finland</td>
<td>1999–2010</td>
<td>0.64–1.1 B</td>
<td>[23,24]</td>
<td></td>
</tr>
<tr>
<td>France</td>
<td></td>
<td>0.7–1.13 B, C</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Germany</td>
<td></td>
<td>0.47–0.73 B, C</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hungary</td>
<td>2004–2010</td>
<td>0.3–0.4 *</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Italy</td>
<td>1999–2010</td>
<td>0.25–0.55 B</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Latvia</td>
<td>2004–2008</td>
<td>0.25–1.03 *</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Poland</td>
<td>1999–2010</td>
<td>0.17–0.84 B</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Serbia</td>
<td>2000</td>
<td>0.9*</td>
<td>[28]</td>
<td></td>
</tr>
<tr>
<td>Slovakia</td>
<td>2004–2010</td>
<td>0.59–0.9 *</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Slovenia</td>
<td>1999–2010</td>
<td>0.3–1.2 *</td>
<td>[23,24]</td>
<td></td>
</tr>
<tr>
<td>Sweden</td>
<td>2004–2010</td>
<td>0.5–0.7 B</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Eastern Mediterranean Region</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No country in this region is in the low rate category</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Region of the Americas</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Argentina</td>
<td>2009</td>
<td>0.6 B</td>
<td>[31]</td>
<td></td>
</tr>
<tr>
<td>Canada</td>
<td>1985–2006</td>
<td>1.4 (pre-vaccine) C [32,33]</td>
<td>Vaccination in 2001–2 in all provinces 0.4 (post-vaccine)</td>
<td></td>
</tr>
</tbody>
</table>
Chile 1998–2006 0.8 B
Columbia 0.3 Y[19]
Mexico 0.1 C
USA 2000–2009 0.8 (pre-vaccine) Equal B, C, Y [34] Routine vaccination program started in 2005 0.3 (post-vaccine)
Venezuela 0.3 Y [19]

South-East Asia Region
Korea 2002–2008 <0.1 [35]
Thailand 2007–2008 <0.1 [36] Higher in <5 year olds

Western Pacific Region
China 2000 onward <0.2 A, C [37,38]
Japan 1999–2004 <0.02 * [39]
Philippines 2004–2008 <0.1 A [1]
Singapore 2005–2009 0.1–0.2 [36,40]

Eastern Mediterranean Region
No country in this region is in the low rate category
*Data not available.

Figure 2. Distribution of common and predominant meningococcal serogroups by region. Predominant strains are highlighted in bold text

The utmost occurrence is in babies less than one year of age, and a minor increase in incidence arises in adolescents and young adults. In one survey in the meningitis belt, the age-occurrence did not upland until the late 20s.
The extensive and fast application of efficient antibiotics has supplied to overthrow the case casualty rate of IMD among 10 and 20 percent, but it is usually advanced in developing countries where admittance to higher stages of concern may be interrupted [52]. Despite advances in resuscitative systems, surgical interference, and significant care, there is a relentless mortality in the early hours of septicemia thanks to the quick succession of illness.

Conclusion

IMD is a stern disease that can be quickly progressive with ensuing noteworthy morbidity and mortality. Vaccines are accessible for the mainstream of sero-groups that cause illness and have established effective in tumbling the illness occurrence in nations that have used them at the population level. Management of the universal collision of these vaccines needs having them made accessible in areas that have the highest illness incidence.

This appraisal used accessible data to describe the load of meningococcal illness in dissimilar countries. Nations were categorized based on the illness endemicity, and accessible records on the most widespread serogroups were appraised to allow evidence-based choices on meningococcal vaccine application. These records assisted to notify SAGE’s new suggestions on the exercise of meningococcal vaccines. Restrictions of the assessment comprise elimination of surveys that were not available in English and the lack of a marker of the worth of examination accustomed to derive occurrence rates. It is essential that suitable surveillance developing new molecular epidemiology instruments is executed to acquire epidemiological facts on the load of meningococcal infection in states where these are not recognized. With the certification of a new affordable conjugated vaccine beside serogroup A (certified in Africa) and more lately, a multi factor serogroup B vaccine in Europe inspection will be obligatory to observe the collision of these vaccines throughout straight immunity and direct protection and permit for optimization of vaccination timetables.

References


[29] dissemination/echi/docs/meningoccocal_en.pdf}


